A New Approach to Neurodegeneration

Targeting the immune drivers of Alzheimer’s Disease and beyond

Stay up to date with the latest developments for MITI 101

Sign up for our newsletter

Unlocking neurodegeneration

MindImmune was founded on the important discovery that inflammatory processes may be at the core causes of neurodegenerative diseases like Alzheimer’s. This discovery has resulted in a new treatment options that act outside of the brain.

Supported by leading Investors
Discovery

The way that specific immune cells react to amyloid plaques is central to the onset and progression of Alzheimer's Disease. MindImmune targets these cells before they migrate into the brain and cause harm.

Hypothesis

By blocking a key receptor, MindImmune can keep harmful immune cells from infiltrating the brain and causing neuronal damage.

First-in-Class Therapeutic

MITI-101 is a monoclonal antibody that prevents neuroinflammation, neurite damage, and vascular pathology—key aspects of Alzheimer's Disease.

MITI-101 will begin human trial validation in early 2027

Our team

MindImmune brings decades of research and operational experience from a world class team

Leadership
Advisors
Isaac Stoner, MBA
CEO

Mark Forman, MD, PhD
CMO

Leonid Gorelik, PhD, MS
CSO

Ed Sullivan
CFO

Thomas Prod'homme, PhD
VP Preclinical Development

Robert Nelson, PhD
VP Biology

Stevin Zorn, PhD
Founder

Brad Margus
Board Chair

Reetika Bhardwaj, PhD, MBA

Christopher O'Donnell, PhD

John Dunlop

LATEST NEWS

MindImmune Caps Off a $30M Series A Round

Dec 1, 2025

MindImmune has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic.

View Article

Latest news

Latest

MindImmune Caps Off a $30M Series A Round

December 1, 2025

MindImmune, a University of Rhode Island based company, has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic.

View Article
Latest

MindImmune Therapeutics Announces $12.4 million Series A Financing

June 13, 2022

Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.

View Article
Latest

MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development

April 17, 2025

Accomplished immunologist brings 15 years of experience in preclinical development, translational biology and drug discovery

View Article